SGLT2 Inhibitor vs GLP-1 Agonist — Metabolic Deal Terms Comparison
Market Analysis
In metabolic, SGLT2 Inhibitor and GLP-1 Agonist represent two of the most actively transacted modalities. At Phase 2, SGLT2 Inhibitor deals carry a median total deal value of $3.6B with $751M upfront, compared to $4.5B total value and $935M upfront for GLP-1 Agonist. The valuation difference reflects distinct risk-reward profiles, manufacturing complexity, and competitive dynamics.
Milestone structures diverge between the two modalities. SGLT2 Inhibitor development milestones average $506M versus $647M for GLP-1 Agonist. Commercial milestones are $1.7B for SGLT2 Inhibitor and $2.2B for GLP-1 Agonist. Royalty rates range from 15%-27.5% for SGLT2 Inhibitor and 16.1%-29.5% for GLP-1 Agonist.
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
How do SGLT2 Inhibitor and GLP-1 Agonist deal terms compare in metabolic?
Which modality commands higher royalty rates: SGLT2 Inhibitor or GLP-1 Agonist?
How do milestone structures differ between SGLT2 Inhibitor and GLP-1 Agonist?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.
Start CalculatingNeed the full deal landscape?
The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.